You are here
Persistent Clinical Improvements, Prolonged Survival Observed in Treprostinil Study of Patients With Pulmonary Hypertension
Jean-Luc Vachiery MD, Associate Professor of Cardiology at the Erasme Hospital in Brussels, Belgium, presented long-term data that showed persistent clinical improvements and prolonged survival in a multi-center cohort of 112 pulmonary arterial hypertension patients treated with Remodulin for up to 57 months. Dr. Vachiery reported that patients improved functional class by more than 35% and their exercise tolerance improved by more than 150 meters during the study period. The study results also showed that Remodulin's most frequent side effect -- infusion site pain -- only resulted in cessation of therapy in 2% of the study cohort and that the Remodulin dose could routinely be titrated to a therapeutic level very rapidly.
"These multi-center data provide further confirmation that Remodulin therapy offers long-term symptomatic and survival benefit to patients with pulmonary hypertension. In our experience, such data, along with the obvious safety advantages of Remodulin over intravenous Flolan, clearly signify that Remodulin can be used as a first line prostacyclin therapy for the treatment of PAH in the ever-increasing number of patients who are failing oral therapies. Furthermore Remodulin dosing should be aggressive, as our experience shows infusion pain, which dissipates over time, is not a limiting factor in the vast majority of patients; yet the treatment benefit, as with Flolan, is dose-dependant," said Dr Vachiery.
Remodulin (treprostinil sodium) Injection is approved in the United States, Israel and Canada as a continuous subcutaneous infusion for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms, to diminish symptoms associated with exercise. Remodulin should be used only by clinicians experienced in the diagnosis and treatment of pulmonary arterial hypertension.
Source: United Therapeutics Corporation